{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-uk-specific-archiving-and-retention-conditions”
},
“headline”: “SOP for UK-Specific Archiving and Retention Conditions”,
“description”: “This SOP provides detailed procedures for archiving and retention of clinical trial records in the United Kingdom. It ensures compliance with MHRA and GCP requirements, addressing both paper and electronic records, environmental controls, access restrictions, and timelines specific to UK regulations.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-27”,
“dateModified”: “2025-08-27”
}

Standard Operating Procedure for UK-Specific Archiving and Retention Conditions

Purpose

The purpose of this SOP is to define the requirements and detailed procedures for archiving and retention of clinical trial records in the United Kingdom. It ensures compliance with the Medicines and Healthcare products Regulatory Agency (MHRA), UK-GCP, and Data Protection Act (DPA 2018), with emphasis on maintaining data integrity, subject confidentiality, and readiness for regulatory inspection. This SOP also aligns with ICH E6(R2) and reflects UK-specific post-Brexit obligations for record retention.

Scope

This SOP applies to sponsors, CROs, investigators, archivists, data managers, IT administrators, and QA personnel involved in managing trial records. It covers both electronic and paper documents, including Trial Master File (TMF), Investigator Site File (ISF), source documents, informed consent forms, pharmacovigilance records, investigational product documentation, and all data required for MHRA inspection and global regulatory submissions. It also includes guidance on environmental controls for storage facilities, electronic archiving security, and destruction protocols specific to the UK.

Responsibilities

• Sponsor: Ensures long-term archiving of trial documents and sets retention timelines according to MHRA guidance.
• CRO: Implements sponsor-defined archiving processes and provides evidence of compliance.
• Investigator: Retains site-specific essential documents until sponsor confirmation of archive release.
• QA: Audits archiving and retention practices, ensuring facilities and procedures meet MHRA standards.
• IT/Archivist: Maintains secure electronic archives with validated systems, access controls, and disaster recovery plans.

Accountability

The Sponsor’s Head of Clinical Operations is accountable for ensuring that trial records are archived and retained in compliance with MHRA requirements and are accessible for inspection at any time during the mandated retention period.

Procedure

1. Identification of Records for Archiving
1.1 Compile a list of essential documents per ICH GCP Section 8, including TMF, ISF, monitoring visit reports, CRFs, source documents, and safety reports.
1.2 Ensure all records are complete, signed, and dated before transfer to archives.
1.3 Prepare an Archiving Checklist (Annexure-1) to confirm completeness.

2. Retention Timelines (UK Specific)
2.1 Retain trial records for a minimum of 25 years or longer as required by MHRA.
2.2 Retain informed consent forms and subject data in accordance with UK-GDPR and DPA 2018 obligations.
2.3 For pediatric and gene therapy trials, retain records for the subject’s lifetime plus defined regulatory years, as required.
2.4 Record retention decisions in Retention Log (Annexure-2).

3. Storage and Environmental Controls
3.1 Store paper records in fireproof, pest-controlled, temperature- and humidity-monitored facilities.
3.2 Validate electronic archives with audit trails, encryption, and access logs.
3.3 Ensure offsite backup storage is available for redundancy.
3.4 Maintain an Environmental Monitoring Log (Annexure-3).

4. Security and Access Controls
4.1 Limit archive access to authorized personnel only.
4.2 Implement dual authentication for electronic archive access.
4.3 Maintain Archive Access Log (Annexure-4).

5. Document Transfer and Archival Process
5.1 Prepare Transfer Forms with document inventory and unique identifiers.
5.2 Investigator transfers ISF documents to sponsor only after closeout confirmation.
5.3 Sponsor confirms receipt and logs in Archival Receipt Log (Annexure-5).
5.4 Archive all correspondence, approvals, reports, and raw data relevant to UK submissions.

6. Electronic Archiving Validation
6.1 Validate e-archive systems per MHRA and FDA 21 CFR Part 11 equivalence.
6.2 Ensure system provides secure access, version control, and unalterable audit trails.
6.3 Conduct periodic system validation checks and document in e-Archive Validation Log (Annexure-6).

7. Inspection Readiness
7.1 Archive must be inspection-ready, with quick retrieval of documents.
7.2 Perform quarterly mock retrievals and document in Inspection Readiness Log (Annexure-7).

8. Record Destruction
8.1 Records may only be destroyed after expiration of MHRA-mandated retention timelines and sponsor authorization.
8.2 Use certified destruction services with documented proof of destruction.
8.3 Document in Record Destruction Log (Annexure-8).

9. Cross-Border Considerations
9.1 If documents are shared with non-UK authorities, ensure compliance with UK-GDPR transfer mechanisms.
9.2 Maintain logs of all cross-border transfers in Regulatory Transfer Log (Annexure-9).

10. Training and Oversight
10.1 All staff handling archiving must undergo training in MHRA and GCP-specific requirements.
10.2 Maintain training records in Training Log (Annexure-10).

Abbreviations

• SOP: Standard Operating Procedure
• MHRA: Medicines and Healthcare products Regulatory Agency
• TMF: Trial Master File
• ISF: Investigator Site File
• QA: Quality Assurance
• eTMF: Electronic Trial Master File
• DPA: Data Protection Act 2018
• UK-GDPR: UK General Data Protection Regulation

Documents

1. Archiving Checklist (Annexure-1)
2. Retention Log (Annexure-2)
3. Environmental Monitoring Log (Annexure-3)
4. Archive Access Log (Annexure-4)
5. Archival Receipt Log (Annexure-5)
6. e-Archive Validation Log (Annexure-6)
7. Inspection Readiness Log (Annexure-7)
8. Record Destruction Log (Annexure-8)
9. Regulatory Transfer Log (Annexure-9)
10. Training Log (Annexure-10)

References

• MHRA Guidance – Managing Clinical Trial Authorisations
• ICH GCP Guidelines
• UK Data Protection Act 2018

Version: 1.0

Approval Section

Annexures

Annexure-1: Archiving Checklist

Annexure-2: Retention Log

Annexure-3: Environmental Monitoring Log

Annexure-4: Archive Access Log

Annexure-5: Archival Receipt Log

Annexure-6: e-Archive Validation Log

Annexure-7: Inspection Readiness Log

Annexure-8: Record Destruction Log

Annexure-9: Regulatory Transfer Log

Annexure-10: Training Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-25-year-minimum-archiving-and-sponsor-responsibility”
},
“headline”: “SOP for 25-Year Minimum Archiving and Sponsor Responsibility”,
“description”: “This SOP outlines procedures for ensuring compliance with EMA and EU CTR requirements on minimum 25-year archiving of clinical trial records. It defines sponsor responsibilities, secure storage standards, premature destruction prevention, and inspection readiness obligations.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for 25-Year Minimum Archiving and Sponsor Responsibility

Purpose

The purpose of this SOP is to define requirements and processes for archiving essential clinical trial records for a minimum of 25 years, in compliance with the EU Clinical Trials Regulation (EU CTR 536/2014) and EMA guidance. This SOP ensures sponsor accountability for secure, long-term storage of both paper and electronic records.

Scope

This SOP applies to sponsors, CROs, investigators, and QA personnel involved in archiving of trial master files (TMFs), investigator site files (ISFs), safety records, and essential clinical trial documents. It covers responsibilities, archiving standards, premature destruction prevention, and regulatory inspection readiness.

Responsibilities

• Sponsor: Ensures compliance with 25-year archiving, oversees CROs and sites, and funds secure long-term storage.
• Investigator: Maintains investigator site records and ensures transfer to secure archives.
• CRO: Supports sponsor in TMF/ISF maintenance and vendor oversight.
• QA: Audits archive facilities and processes to ensure compliance.
• Archive Vendor: Provides validated storage with environmental and security controls.

Accountability

The Sponsor is ultimately accountable for 25-year record retention compliance, regardless of delegation to CROs or archive vendors.

Procedure

1. Identification of Essential Records
1.1 Identify documents required for 25-year retention under EU CTR.
1.2 Include TMF, ISF, safety reports, informed consent forms, and regulatory correspondence.
1.3 Record in Essential Documents List (Annexure-1).

2. Secure Archiving
2.1 Store documents in validated archive facilities with environmental monitoring (temperature, humidity).
2.2 Maintain access logs.
2.3 Record in Archive Facility Log (Annexure-2).

3. Electronic Records
3.1 Validate electronic archiving systems with audit trails.
3.2 Perform periodic data integrity checks.
3.3 Record in Electronic Archive Log (Annexure-3).

4. Prevention of Premature Destruction
4.1 Records must not be destroyed before 25 years unless authorized by EMA.
4.2 Maintain Destruction Prevention Log (Annexure-4).

5. Access and Confidentiality
5.1 Limit access to authorized staff only.
5.2 Document in Archive Access Log (Annexure-5).

6. Inspection Readiness
6.1 Maintain archives in inspection-ready condition.
6.2 Conduct periodic mock audits recorded in Archive Audit Log (Annexure-6).

Abbreviations

• SOP: Standard Operating Procedure
• TMF: Trial Master File
• ISF: Investigator Site File
• EMA: European Medicines Agency
• EU CTR: European Union Clinical Trials Regulation
• CRO: Contract Research Organization
• QA: Quality Assurance

Documents

1. Essential Documents List (Annexure-1)
2. Archive Facility Log (Annexure-2)
3. Electronic Archive Log (Annexure-3)
4. Destruction Prevention Log (Annexure-4)
5. Archive Access Log (Annexure-5)
6. Archive Audit Log (Annexure-6)

References

• EU Clinical Trials Regulation (EU CTR 536/2014)
• European Medicines Agency (EMA)
• ICH GCP E6(R2)

Version: 1.0

Approval Section

Annexures

Annexure-1: Essential Documents List

Annexure-2: Archive Facility Log

Annexure-3: Electronic Archive Log

Annexure-4: Destruction Prevention Log

Annexure-5: Archive Access Log

Annexure-6: Archive Audit Log

Revision History

For more SOPs visit: Pharma SOP